Exclusive Summary

• Global IP & Freedom to Operate: An innovative drug with global proprietary rights, allowing immediate market entry without waiting for patent expiries or risking infringement, ideal for exclusive regional distribution.
• US Clinical Validation & No Ethnic Difference: The only Chinese GLP-1 to complete Phase II trials in the US, proving no ethnic difference, which significantly lowers regulatory hurdles and facilitates bridging studies in global markets.
• Superior Compliance & Guideline Alignment: Offers a once-weekly injection advantage over daily competitors, aligning with ADA/EASD guidelines for T2DM and Obesity management, ensuring high patient adherence.
• Cost-Effectiveness & Supply Stability: Leverages Chinese manufacturing efficiency to offer a competitive price point against MNC incumbents, making premium GLP-1 therapy accessible in price-sensitive emerging markets.

Asset Materials

Contact Us for Full Materials